Lv3
300 积分 2026-02-02 加入
Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen
2个月前
已完结
A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer
2个月前
已完结
A Phase II Trial of Cardioprotection with Cardioxane (ICRF-187) in Patients with Advanced Breast Cancer Receiving 5-Fluorouracil, Doxorubicin and Cyclophosphamide
2个月前
已完结
Prevention of Chemotherapy-Induced Left Ventricular Dysfunction With Enalapril and Carvedilol: Rationale and Design of the OVERCOME Trial
2个月前
已完结
Protective effects of nebivolol against anthracycline-induced cardiomyopathy: A randomized control study
2个月前
已完结
Challenges in conducting a pediatric longitudinal prevention study: Lessons from the ACE-inhibitor after anthracycline trial
3个月前
已完结
Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up
3个月前
已完结
Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients
3个月前
已完结
Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors
3个月前
已完结
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study—Cancer and Leukemia Group B 9631
3个月前
已完结
皖公网安备34019202002308
